Analyst Price Targets — RLAY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 26, 2026 11:22 am | — | Oppenheimer | $14.00 | $7.43 | TheFly | Relay Therapeutics upgraded to Outperform from Perform at Oppenheimer |
| December 12, 2025 10:21 am | — | Wells Fargo | $13.00 | $7.80 | TheFly | Relay Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo |
| September 16, 2024 6:54 am | Robert Burns | H.C. Wainwright | $19.00 | $7.60 | StreetInsider | Relay Therapeutics (RLAY) PT Raised to $19 at H.C. Wainwright |
| September 10, 2024 4:43 am | Akash Tewari | Jefferies | $16.00 | $9.51 | TheFly | Relay Therapeutics upgraded to Buy from Hold at Jefferies |
| September 9, 2024 3:50 pm | Peter Lawson | Barclays | $17.00 | $9.51 | TheFly | Relay Therapeutics price target raised to $17 from $14 at Barclays |
| September 4, 2024 10:00 am | Jason Gerberry | Bank of America Securities | $20.00 | $6.41 | StreetInsider | Relay Therapeutics (RLAY) PT Lowered to $20 at BofA Securities |
| May 10, 2024 3:25 am | Peter Lawson | Barclays | $15.00 | $6.68 | StreetInsider | Barclays Upgrades Relay Therapeutics (RLAY) to Overweight |
| May 6, 2024 7:53 am | Matt Biegler | Oppenheimer | $25.00 | $7.04 | StreetInsider | Relay Therapeutics (RLAY) PT Lowered to $25 at Oppenheimer |
| April 20, 2023 12:58 am | Akash Tewari | Jefferies | $12.50 | $12.35 | StreetInsider | Jefferies Upgrades Relay Therapeutics (RLAY ) to Hold |
| February 3, 2023 5:03 am | — | Oppenheimer | $33.00 | $22.76 | Benzinga | Oppenheimer Initiates Coverage On Relay Therapeutics with Outperform Rating, Announces Price Target of $33 |
Latest News for RLAY
Shares of Relay Therapeutics, Inc. (NASDAQ: RLAY - Get Free Report) hit a new 52-week high on Friday after the company announced better than expected quarterly earnings. The stock traded as high as $10.99 and last traded at $11.2970, with a volume of 1751195 shares traded. The stock had previously closed at $9.16. The company reported
Casdin Capital bought 1,662,193 shares of Relay Therapeutics; the estimated trade size was $11.86 million. Meanwhile, the quarter-end position value rose by $50.81 million, reflecting both trading and price appreciation.
Relay Therapeutics, Inc. (RLAY) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.45 per share a year ago.
Initial Phase 1 data of zovegalisib in PIK3CA-driven vascular anomalies expected to be announced in first half of 2026 Breast cancer triplet data and frontline Phase 3 plans expected to be announced in 2026 Initial Phase 1/2 data of zovegalisib + fulvestrant at 400mg BID fed (Phase 3 dose) in CDK4/6-experienced patients to be presented at ESMO TAT on March 16, 2026 Approximately $555 million in cash, cash…
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in March:
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RLAY.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.